Cargando…

Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study

BACKGROUND: To retrospectively assess the efficacy and safety of Vinflunine (VFL) under routine conditions and identify overall survival (OS) prognostic factors. METHODS: Twenty centres participated in the retrospective study (minimum 4 patients undergoing VFL treatment for advanced/metastatic UC af...

Descripción completa

Detalles Bibliográficos
Autores principales: Médioni, Jacques, Di Palma, Mario, Guillot, Aline, Spaeth, Dominique, Théodore, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792100/
https://www.ncbi.nlm.nih.gov/pubmed/26975779
http://dx.doi.org/10.1186/s12885-016-2262-9
_version_ 1782421194376478720
author Médioni, Jacques
Di Palma, Mario
Guillot, Aline
Spaeth, Dominique
Théodore, Christine
author_facet Médioni, Jacques
Di Palma, Mario
Guillot, Aline
Spaeth, Dominique
Théodore, Christine
author_sort Médioni, Jacques
collection PubMed
description BACKGROUND: To retrospectively assess the efficacy and safety of Vinflunine (VFL) under routine conditions and identify overall survival (OS) prognostic factors. METHODS: Twenty centres participated in the retrospective study (minimum 4 patients undergoing VFL treatment for advanced/metastatic UC after platinum-based regimen progression. Primary endpoint was OS. Secondary endpoints: progression-free survival (PFS), radiological response rate (RR) RECIST criteria and toxicity (CTC NCI v3). RESULTS: These centres enrolled 134 patients. Prior chemotherapy (CT) lines (≥1 palliative): 1 and ≥2 in 69 % and 26 % of patients, respectively. Performance status (PS): 0, 1, 2 in 25 %, 46 % and 23 % of patients. Median OS = 8.2 months [6.5–9.4], PFS = 4.2 months and RR 22 %, median number of 5 cycles. In risk groups based on 0–3 presence of adverse prognostic factors (PS ≥1, haemoglobin ≤10 g/dl and liver metastasis), median OS: 13.2, 9.9, 3.6, and 2.4 months (P < .0001), respectively; 3.3 months (1.9–5.6) in PS ≥ 2 subgroup. CONCLUSION: This study reflects routine UC management and confirmed VFL patient efficacy. The drug is safe with gastro-intestinal and haematological prophylaxis. Analysis of prognostic factors for OS is consistent with pivotal trials.
format Online
Article
Text
id pubmed-4792100
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47921002016-03-16 Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study Médioni, Jacques Di Palma, Mario Guillot, Aline Spaeth, Dominique Théodore, Christine BMC Cancer Research Article BACKGROUND: To retrospectively assess the efficacy and safety of Vinflunine (VFL) under routine conditions and identify overall survival (OS) prognostic factors. METHODS: Twenty centres participated in the retrospective study (minimum 4 patients undergoing VFL treatment for advanced/metastatic UC after platinum-based regimen progression. Primary endpoint was OS. Secondary endpoints: progression-free survival (PFS), radiological response rate (RR) RECIST criteria and toxicity (CTC NCI v3). RESULTS: These centres enrolled 134 patients. Prior chemotherapy (CT) lines (≥1 palliative): 1 and ≥2 in 69 % and 26 % of patients, respectively. Performance status (PS): 0, 1, 2 in 25 %, 46 % and 23 % of patients. Median OS = 8.2 months [6.5–9.4], PFS = 4.2 months and RR 22 %, median number of 5 cycles. In risk groups based on 0–3 presence of adverse prognostic factors (PS ≥1, haemoglobin ≤10 g/dl and liver metastasis), median OS: 13.2, 9.9, 3.6, and 2.4 months (P < .0001), respectively; 3.3 months (1.9–5.6) in PS ≥ 2 subgroup. CONCLUSION: This study reflects routine UC management and confirmed VFL patient efficacy. The drug is safe with gastro-intestinal and haematological prophylaxis. Analysis of prognostic factors for OS is consistent with pivotal trials. BioMed Central 2016-03-14 /pmc/articles/PMC4792100/ /pubmed/26975779 http://dx.doi.org/10.1186/s12885-016-2262-9 Text en © Médioni et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Médioni, Jacques
Di Palma, Mario
Guillot, Aline
Spaeth, Dominique
Théodore, Christine
Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study
title Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study
title_full Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study
title_fullStr Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study
title_full_unstemmed Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study
title_short Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study
title_sort efficacy and safety of vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the french multi-centre curve study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792100/
https://www.ncbi.nlm.nih.gov/pubmed/26975779
http://dx.doi.org/10.1186/s12885-016-2262-9
work_keys_str_mv AT medionijacques efficacyandsafetyofvinflunineforadvancedormetastaticurothelialcarcinomainroutinepracticebasedonthefrenchmulticentrecurvestudy
AT dipalmamario efficacyandsafetyofvinflunineforadvancedormetastaticurothelialcarcinomainroutinepracticebasedonthefrenchmulticentrecurvestudy
AT guillotaline efficacyandsafetyofvinflunineforadvancedormetastaticurothelialcarcinomainroutinepracticebasedonthefrenchmulticentrecurvestudy
AT spaethdominique efficacyandsafetyofvinflunineforadvancedormetastaticurothelialcarcinomainroutinepracticebasedonthefrenchmulticentrecurvestudy
AT theodorechristine efficacyandsafetyofvinflunineforadvancedormetastaticurothelialcarcinomainroutinepracticebasedonthefrenchmulticentrecurvestudy